CellCentric
BiotechnologyView the employees at
CellCentric-
Kate Fisher Clinical Trials Manager at CellCentric
-
Congleton, England, United Kingdom
-
Rising Star
Neil Pegg CSO, Board Member at Cellcentric Ltd-
Top 5%
Elaine Gilmore Clinical Research Associate at CELLCENTRIC LIMITED-
York, England, United Kingdom
-
Rising Star
Will West Biotech CEO, Chairman, Director.-
Top 5%
Laura Johnson Clinical Trial Manager at CellCentric-
Manchester Area, United Kingdom
-
Rising Star
Overview
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.
-